is an important cause of bleeding in patients with cirrhosis associated with portal hypertension. Histologically, the condition is characterized by dilation of the mucosal and submucosal vessels ...

Treatment for portal hypertension in patients with cirrhosis is based on the use of β-blockers with or without organic nitrates; however, these agents are effective in less than 50% of patients ...

Consecutive patients with laparoscopic splenectomy seen at the Department of Surgery and Sciences at Kyushu University from January 2003 to December 2006 were included if they had cirrhosis and ...

The findings were, as expected, those of cirrhosis of the liver ("postnecrotic" type by microscopical examination) and portal hypertension. The portal pressure was equivalent to 31 cm. of saline ...

In addition, cirrhosis distorts the liver's structure, causing blood congestion in the portal vein and, ultimately, raising ...

Patient population for the NAVIGATE trial is based on non-invasive tests and clinical criteria utilizing latest treatment guidelines for portal ...

Galectin Therapeutics (GALT) announced the presentation of three posters on the ongoing NAVIGATE trial in patients with MASH cirrhosis and ...

The FDA in 2016 granted accelerated approval to the FXR agonist as a second-line treatment for adults with PBC, either in ...